Prescribe psilocybine or MDMA

​​​​​​​Approval from NSW Health is required to prescribe, supply or administer psilocybine or MDMA​.

There are currently no psilocybine or MDMA products registered on the Australian Register of Therapeutic Goods (ARTG). Access is available only through the Therapeutic Goods Administration (TGA) Authorised Prescriber Scheme and NSW Health approval requirements.

Note: A NSW Health approval is different from a PBS Authority approval. A PBS Authority provides access to a medicine at a subsidised cost, while a NSW Health approval authorises prescribing, supplying or administering the medicine in circumstances specified under NSW legislation.

On this page

​Access pathway for psilocybine and MDMA​​

Since July 2023, Schedule 8 of Poisons Standar​d​ has included:

  • psilocybine for the treatment of treatment-resistant depression (TRD)
  • MDMA for the treatment of post-traumatic stress disorder (PTSD).

Only Ahpra-registered psychiatrists authorised under the TGA Authorised Prescriber Scheme​ and approved by NSW Health may prescribe, supply or administer these substances in NSW.

Access is limited to:

  • ​psilocybine for the treatment of treatment-resistant depression
  • MDMA for the treatment of post-traumatic stress disorder.

The use of psilocybine or MDMA for any other purpose remains limited to approved medical or scientific research, including clinical trials. For more information, see Clinical trial schemes.

[back to top]​

​

​Applying for approval

​Before applying to NSW Health, a psychiatrist must obtain authorisation under the TGA Authorised Prescriber Scheme​. To become an authorised prescriber, the psychiatrist must:

  • ​obtain approval from a Human Research Ethics Committee (HREC), and
  • obtain approval from the TGA under the Authorised Prescriber Scheme.

Further information is available from the TGA's Access pathways for MDMA and psilocybine​​.

​Once authorised by the TGA, psychiatrists must submit an ​Application for approval - Psilocybine or MDMA​ to NSW Health​.

Before applying, refer to the guidance provided in Approval applications - supplementary information.

Application processing times

Applications are generally processed within 30 business days.

How applications are assessed

Applications are generally approved where the applicant:

  • is an Ahpra-registered psychiatrist
  • holds approval under the TGA Authorised Prescriber Scheme
  • proposes treatment for:
    • treatment-resistant depression (psilocybin), or
    • post-traumatic stress disorder (MDMA)
  • will provide treatment in a healthcare setting that meets the required monitoring and safety standards.

[back to top]​

​​Access to psilocybine or MDMA products

Once all approvals and authorisations have been obtained, the authorised psychiatrist, or a person acting on their behalf, may also need to obtain an import licence and permit from the Office of Drug Control to import products containing psilocybine or MDMA. For further information please see TGA.

NSW treatment ​data requests

NSW Health requires the submission of treatment and adverse event data at 3, 6 and 12 months following completion of a treatment course. These are to be submitted Data collection form.

Current as at: Thursday 5 November 2026
Contact page owner: Pharmaceutical Services